Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
489 studies found for:    "Squamous cell carcinoma of the head and neck"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Conditions: Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC) Patients Who Are Resistant or Ineligible/Intolerant to Platinum-based Chemotherapy.;   Recurrent Head and Neck Squamous Cell Carcinoma;   Metastatic Head and Neck Squamous Cell Carcinoma
Interventions: Drug: BYL719 as film-coated (FC) whole tablets;   Drug: BYL719 as dispersible tablets (DT);   Biological: cetuximab;   Drug: BYL719 as film-coated (FC) drink suspension
2 Completed A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer
Conditions: HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma;   HER2 + Breast Cancer;   HER2 + Gastric Cancer;   Squamous Cell Carcinoma of Head and Neck;   Esophageal Squamous Cell Carcinoma
Intervention: Drug: LJM716
3 Not yet recruiting Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
Conditions: Cancer of Head and Neck;   Head and Neck Cancer;   Neoplasms, Head and Neck;   Carcinoma, Squamous Cell of Head and Neck;   Squamous Cell Carcinoma of the Head and Neck;   Squamous Cell Carcinoma, Head and Neck
Interventions: Biological: MK-3475;   Procedure: Surgery;   Radiation: Intensity modulated radiation therapy;   Radiation: Image-guided radiation therapy;   Drug: Cisplatin
4 Terminated EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck
Intervention: Drug: EMD 1201081 + 5-FU + Cisplatin + Cetuximab
5 Completed
Has Results
EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck Cancer
Interventions: Drug: Cetuximab;   Drug: EMD 1201081
6 Active, not recruiting E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
Condition: Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: E7050;   Drug: Cetuximab
7 Unknown  Study of 3-Dimensional Conformal Radiotherapy (3D-CRT) Versus Intensity Modulated Radiotherapy (IMRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Radiation: 3 Dimensional Radiation Therapy;   Radiation: Intensity Modulated Radiation Therapy
8 Recruiting A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Afatinib;   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Cisplatin;   Radiation: Intensity Modulated Radiation Therapy
9 Recruiting ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Cetuximab;   Procedure: Surgery;   Radiation: Post-surgical radiation;   Drug: Cisplatin or carboplatin
10 Recruiting Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Condition: Carcinoma, Squamous Cell of Head and Neck
Interventions: Drug: VTX-2337;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: 5-fluorouracil;   Drug: Placebo
11 Unknown  Combined FDG PET/CT Imaging in Response Evaluation After Radiochemotherapy in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Condition: Locally Advanced Squamous Cell Carcinoma of the Head and Neck Region
Intervention: Other: Integrated FDG PET/CT
12 Recruiting Evaluation of Afatinib in Maintenance Therapy in Squamous Cell Carcinoma of the Head and Neck
Condition: Head and Neck Squamous Cell Carcinoma
Interventions: Drug: AFATINIB;   Drug: Placebo of  AFATINIB
13 Active, not recruiting IAEA-HypoX. Accelerated Radiotherapy With or Without Nimorazole in Squamous Cell Carcinoma of the Head and Neck
Condition: Head and Neck Carcinoma
Interventions: Radiation: Accl. RT;   Radiation: Accl. radiotherapy + Nimorazole
14 Not yet recruiting Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma
Condition: Carcinoma, Squamous Cell of Head and Neck
Interventions: Drug: Ficlatuzumab;   Drug: Cisplatin;   Radiation: Intensity Modulated Radiotherapy (IMRT)
15 Active, not recruiting Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck
Intervention: Biological: Dalantercept
16 Recruiting Collection of Plasma Samples for Squamous Cell Carcinoma of the Head and Neck Patients
Condition: Squamous Cell Carcinoma of the Head and Neck
Intervention: Other: Plasma samples
17 Unknown  Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions: Drug: Bevacizumab;   Drug: erlotinib;   Drug: Sulindac
18 Completed Study of Docetaxel in Combination With Cisplatin and 5-Fluorouracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Conditions: Advanced Squamous Cell Carcinoma;   Squamous Cell Carcinoma of Head and Neck;   SSCHN
Interventions: Drug: Docetaxel;   Drug: Cisplatin;   Drug: 5-Fluorouracil
19 Not yet recruiting Window Trial 5-aza in HNSCC, T-tare
Condition: Head and Neck Squamous Cell Carcinoma
Intervention: Drug: 5-Azacitadine
20 Unknown  Erlotinib, Radiation Therapy and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Erlotinib clorhidrate;   Drug: Cisplatin;   Procedure: Radiation therapy

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years